A Randomized Phase 3 Trial of Zanubrutinib versus Ibrutinib in Symptomatic Waldenstrom Macroglobulinemia: THE ASPEN STUDY
An International Multicenter Retrospective Analysis of Patients With Extranodal Marginal Zone Lymphoma and Histologically Confirmed Central Nervous System and Dural Involvement
Phase 1 study of selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study
